Laura Cohen, MD
Cardiovascular Disease · Boston, MANPI 1326466509
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,102 of the $5,971 with a category attached, or 85.4%. AstraZeneca accounts for 92.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $5,142 and has fallen 99.1% since, to $44 in 2025.
Across 13 payments — averaging $459.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Abbott$231
- Astellas Pharma US Inc$75
- Stryker$45
- Alnylam Pharmaceuticals Inc.$44
- Kerecis Limited$40
- plus $15 from 1 others
Across 1 payment — averaging $50,029 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$50K
What the payments were for
- Consulting fees$5,10285%
- Food & beverage$58610%
- Education$2845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $5,521 |
| Abbott | 2 | $231 |
| Astellas Pharma US Inc | 1 | $75 |
| Stryker | 2 | $45 |
| Alnylam Pharmaceuticals Inc. | 1 | $44 |
| Kerecis Limited | 1 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$264
- Ensite Cardiac Mapping System$209
- FARXIGA$134
How this compares
$5,971 in reported general payments places this provider in the 70th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $73,484 |
| JardianceEmpagliflozin | 68 | $65,605 |
| EntrestoSacubitril/Valsartan | 54 | $62,028 |
| OzempicSemaglutide | 16 | $15,301 |
| Repatha SureclickEvolocumab | 13 | $8,108 |
| Metoprolol Succinate | 119 | $2,685 |
| Rosuvastatin Calcium | 57 | $1,900 |
| Ezetimibe | 40 | $1,691 |
| Atorvastatin Calcium | 99 | $1,481 |
| Valsartan | 15 | $910 |
| Ranolazine ErRanolazine | 11 | $759 |
| Spironolactone | 54 | $751 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 33 | $489 |
| Amlodipine Besylate | 52 | $452 |
| ClopidogrelClopidogrel Bisulfate | 22 | $323 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.